查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1967595

PARP抑制剂生物标记市场－全球产业规模、份额、趋势、机会、预测：按产品、服务、应用、地区和竞争对手划分，2021-2031年

PARP Inhibitor Biomarkers Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product, By Services, By Application, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

全球 PARP 抑制剂生物标记市场预计将从 2025 年的 9.4214 亿美元成长到 2031 年的 15.6361 亿美元，复合年增长率达到 8.81%。

这些生物标记，包括BRCA突变和同源重组缺陷等特定分子指标，对于识别可能对聚（ADP-核糖）聚合酵素抑制剂疗法产生反应的癌症患者至关重要。市场成长主要受精准医疗的进步以及越来越多的伴随诊断获准用于卵巢、乳癌和前列腺癌治疗的监管核准的推动。这些恶性肿瘤发生率的上升进一步刺激了市场需求，因为有效的治疗方案製定需要严格的诊断筛检。例如，美国癌症协会预测，到2025年，美国将新增约313,780例前列腺癌病例，凸显了准确评估生物标记以确保最佳治疗管理的迫切需求。

市场概览
预测期 2027-2031
市场规模：2025年 9.4214亿美元
市场规模：2031年 1,563,610,000 美元
复合年增长率：2026-2031年 8.81%
成长最快的细分市场 成套工具
最大的市场 北美洲

儘管基因组分析发展势头强劲，但其高成本和复杂的报销机制仍使其面临许多挑战。全球医疗体系间保险覆盖政策的不一致和监管要求的差异，会严重限制患者获得必要的伴随诊断。这些经济和行政障碍可能会阻碍生物标记检测的临床应用，并限制整个产业的成长，尤其是在价格敏感型市场。

市场驱动因素

全球BRCA相关癌症发生率的不断上升是生物标记市场发展的重要驱动因素，也因此迫切需要可靠的诊断筛检来识别适合PARP抑制剂治疗的患者。随着乳癌、卵巢和胰臟癌等恶性肿瘤发生率的持续增长，检测种系和体细胞突变的临床需求也日益增加。患者数量的增长与伴随诊断的使用直接相关，因为识别BRCA1/2突变通常是标靶治疗的监管前提条件。根据美国癌症协会2024年1月发布的《2024年癌症事实与数据》报告，预计美国女性将新增310,720例侵袭性乳癌病例，这意味着有大量患者需要进行基因组评估以製定有效的治疗方案。

同时，临床上对同源重组缺陷 (HRD) 分层和全面基因组分析的需求日益增长，正在加速市场发展。临床医师正从单一基因检测转向能够捕捉更广泛基因组不稳定性标记的广谱检测，这一趋势得益于次世代定序(NGS) 技术的进步。精准肿瘤学领域诊断服务的快速发展也凸显了这种向更全面的分子表征发展的趋势。例如，Myriad Genetics 在 2024 年 2 月报告称，其全年检测量同比增长 35%，凸显了其诊断服务的广泛应用。 Guardant Health 在 2024 年 2 月发布的报告进一步印证了这一强劲的需求，该公司在 2023 年为临床客户提供了 172,900 次检测，同比增长 39%。

市场挑战

全面的基因组分析成本高且报销流程复杂，是全球PARP抑制剂生物标记市场成长的主要障碍。这些经济障碍直接阻碍了伴随诊断的广泛应用，而伴随诊断对于PARP抑制剂疗法的处方至关重要。当保险拒付或患者需承担高额自付费用时，这些关键检测的临床应用往往会停滞不前。因此，标靶治疗的目标患者群无法充分识别，诊断开发商和製药公司的获利能力也受到极大限制。

此外，不同医疗体系间行政管理的不一致加剧了这项挑战，阻碍了医疗产业在价格敏感地区充分发挥其潜力。这种情况造成了监管核准与病人实际就医之间的差距，经济摩擦也阻碍了医疗服务提供者进行必要的筛检检测。美国临床肿瘤学会（ASCO）发布的一项2025年研究预测，晚期癌症的分子检测率将维持在低于35%的水平，凸显了由于就医障碍导致的临床指南与实际应用之间持续存在的差距。如果没有统一的报销机制，就很难将恶性肿瘤发生率的上升趋势与可持续的经济成长联繫起来。

市场趋势

目前，液态生物检体在非侵入性生物标记分析和纵向监测方面的应用显着增长。临床医生正在扩大循环肿瘤DNA (ctDNA) 分析的应用范围，以克服基于组织样本的局限性，例如肿瘤异质性和重复切片检查的侵入性。该技术能够即时追踪微量残存疾病(MRD) 并早期发现抗药性机制，这对于优化PARP抑制剂治疗方案至关重要。这些以血液为基础的诊断技术的快速普及也反映在产业绩效指标中。根据Natera公司截至2025年2月的财年财务报告，该公司在2024年处理了约528,200例肿瘤检测，年增54.9%，凸显了市场对非侵入性分子监测日益增长的需求。

同时，人工智慧的整合正在革新基因组变异解读，以应对大规模定序资料的复杂性。随着诊断检测范围的扩大，涵盖了全面的同源重组修復（HRR）基因，检查室在对意义未明的变异（VUS）进行分类方面面临着瓶颈。目前，人工智慧驱动的平台正被部署用于自动化变异註释、提高分类准确率并加快关键治疗决策的周转时间。这种数位转型使分散式检查网路能够有效率地扩展其精准医疗能力。例如，SOPHiA GENETICS在2025年3月报告称，其数据驱动型医疗保健平台在2024年完成了创纪录的35.2万次分析。这反映出处理量年增11%，主要得益于先进分析工具的引进。

目录

第一章概述

第二章：调查方法

第三章执行摘要

第四章：客户心声

第五章：全球PARP抑制剂生物标记市场展望

  • 市场规模及预测
    • 按金额
  • 市占率及预测
    • 依产品分类（试剂盒、检测方法）
    • 服务故障（BRCA1 和 BRCA2 检测、HRD 检测、HRR 检测、其他）
    • 依应用领域（乳癌、卵巢癌等）
    • 按地区
    • 按公司（2025 年）
  • 市场地图

第六章：北美PARP抑制剂生物标记市场展望

  • 市场规模及预测
  • 市占率及预测
  • 北美洲：国别分析
    • 我们
    • 加拿大
    • 墨西哥

第七章：欧洲PARP抑制剂生物标记市场展望

  • 市场规模及预测
  • 市占率及预测
  • 欧洲：国别分析
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙

第八章：亚太地区PARP抑制剂生物标记的市场展望

  • 市场规模及预测
  • 市占率及预测
  • 亚太地区：国别分析
    • 中国
    • 印度
    • 日本
    • 韩国
    • 澳洲

第九章：中东和非洲PARP抑制剂生物标记的市场展望

  • 市场规模及预测
  • 市占率及预测
  • 中东与非洲：国别分析
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 南非

第十章：南美洲PARP抑制剂生物标记市场展望

  • 市场规模及预测
  • 市占率及预测
  • 南美洲：国别分析
    • 巴西
    • 哥伦比亚
    • 阿根廷

第十一章 市场动态

  • 促进因素
  • 任务

第十二章 市场趋势与发展

  • 併购
  • 产品发布
  • 近期趋势

第十三章：全球PARP抑制剂生物标记市场：SWOT分析

第十四章：波特五力分析

  • 产业竞争
  • 新进入者的潜力
  • 供应商的议价能力
  • 顾客权力
  • 替代品的威胁

第十五章 竞争格局

  • Myriad Genetics, Inc.
  • Ambry Genetics
  • Thermo Fisher Scientific, Inc.
  • Illumina, Inc.
  • CENTOGENE NV
  • Amoy Diagnostics Co., Ltd.
  • Invitae Corporation
  • NeoGenomics Laboratories
  • QIAGEN NV
  • Agilent Technologies, Inc.

第十六章 策略建议

第十七章：关于研究公司及免责声明

简介目录
Product Code: 27188

The Global PARP Inhibitor Biomarkers Market is projected to expand from USD 942.14 Million in 2025 to USD 1563.61 Million by 2031, achieving a CAGR of 8.81%. These biomarkers, which encompass specific molecular indicators like BRCA mutations and homologous recombination deficiency status, are essential for identifying cancer patients who are likely to respond to poly (ADP-ribose) polymerase inhibitor treatments. The market's growth is primarily fueled by the advancing paradigm of precision medicine and the increasing number of regulatory approvals for companion diagnostics utilized in ovarian, breast, and prostate cancer care. This demand is further bolstered by the rising prevalence of these malignancies, which mandates rigorous diagnostic screening for effective treatment planning; for instance, the American Cancer Society expects approximately 313,780 new prostate cancer cases to be diagnosed in the United States in 2025, underscoring the significant need for accurate biomarker assessment to ensure optimal therapeutic management.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 942.14 Million
Market Size 2031USD 1563.61 Million
CAGR 2026-20318.81%
Fastest Growing SegmentKits
Largest MarketNorth America

Despite this robust growth trajectory, the market encounters significant challenges stemming from the high costs and complex reimbursement structures associated with comprehensive genomic profiling. Inconsistent insurance coverage policies and varied regulatory requirements across different global healthcare systems can severely restrict patient access to necessary companion diagnostics. These economic and administrative hurdles have the potential to hinder the broader clinical adoption of biomarker testing and constrain the overall expansion of the sector, particularly in markets that are highly sensitive to price.

Market Driver

The increasing global prevalence of BRCA-associated cancers serves as a fundamental driver for the biomarker market, creating an urgent need for robust diagnostic screening to identify patients eligible for PARP inhibitor therapy. As the incidence of malignancies such as breast, ovarian, and pancreatic cancers continues to rise, the clinical imperative to detect germline and somatic mutations has intensified. This growing patient volume correlates directly with the utilization of companion diagnostics, as the identification of BRCA1/2 mutations is frequently a regulatory prerequisite for prescribing targeted therapies. According to the American Cancer Society's "Cancer Facts & Figures 2024" report from January 2024, an estimated 310,720 new cases of invasive breast cancer were projected to be diagnosed in women in the United States, establishing a substantial baseline of patients requiring genomic evaluation for effective treatment planning.

Concurrently, the market is being accelerated by the growing clinical demand for Homologous Recombination Deficiency (HRD) stratification and comprehensive genomic profiling. Clinicians are increasingly transitioning from single-gene testing to broader panels that capture a wider array of genomic instability markers, a shift supported by advancements in Next-Generation Sequencing (NGS) technologies. This trend toward more extensive molecular characterization is evidenced by the rapid uptake of diagnostic services within the precision oncology sector. For instance, Myriad Genetics reported in February 2024 that its full-year testing volume grew by 35% year-over-year, highlighting the surge in diagnostic adoption. This strong demand is further illustrated by Guardant Health, which reported in February 2024 that it provided 172,900 tests to clinical customers in 2023, representing a 39% increase compared to the prior year.

Market Challenge

The substantial cost and reimbursement complexities linked to comprehensive genomic profiling present a formidable barrier to the growth of the Global PARP Inhibitor Biomarkers Market. These financial obstacles directly impede the widespread adoption of companion diagnostics, which are strictly required for prescribing PARP inhibitor therapies. When insurance policies deny coverage or impose significant out-of-pocket expenses, the clinical uptake of these critical tests often stagnates. Consequently, the pool of patients eligible for targeted therapies remains under-identified, which effectively limits the revenue potential for both diagnostic developers and pharmaceutical companies.

Furthermore, administrative inconsistencies across various healthcare systems exacerbate this challenge, preventing the sector from achieving its full potential in price-sensitive regions. This situation creates a disconnect between regulatory approval and actual patient access, as economic friction discourages healthcare providers from ordering necessary screens. According to a 2025 study highlighted by the American Society of Clinical Oncology, the molecular testing rate for advanced cancers remained at a suboptimal 35%, underscoring the persistent gap between clinical guidelines and actual utilization due to access barriers. Without consistent reimbursement pathways, the market struggles to convert the rising prevalence of malignancies into sustained economic expansion.

Market Trends

The market is currently experiencing a significant shift toward the use of liquid biopsy for non-invasive biomarker profiling and longitudinal monitoring. Clinicians are increasingly adopting circulating tumor DNA (ctDNA) analysis to address the limitations of tissue-based sampling, such as tumor heterogeneity and the invasive nature of repeat biopsies. This method facilitates real-time tracking of Minimal Residual Disease (MRD) and the early detection of resistance mechanisms, both of which are critical for optimizing PARP inhibitor regimens. The rapid adoption of these blood-based diagnostics is reflected in industrial performance metrics; according to Natera's February 2025 financial results, the company processed approximately 528,200 oncology tests in 2024, a substantial 54.9% increase compared to the prior year, underscoring the surging demand for non-invasive molecular monitoring.

Simultaneously, the integration of artificial intelligence is revolutionizing genomic variant interpretation to manage the complexity of large-scale sequencing data. As diagnostic panels expand to include comprehensive homologous recombination repair (HRR) genes, laboratories face a bottleneck in classifying Variants of Uncertain Significance (VUS). AI-driven platforms are now being deployed to automate variant curation, improve classification accuracy, and accelerate turnaround times for critical treatment decisions. This digital transformation enables decentralized testing networks to scale their precision medicine capabilities efficiently. As evidence of this trend, SOPHiA GENETICS reported in March 2025 that it performed a record 352,000 analyses globally on its data-driven medicine platform in 2024, reflecting an 11% year-over-year volume growth driven by the adoption of these advanced analytical tools.

Key Market Players

  • Myriad Genetics, Inc.
  • Ambry Genetics
  • Thermo Fisher Scientific, Inc.
  • Illumina, Inc.
  • CENTOGENE N.V.
  • Amoy Diagnostics Co., Ltd.
  • Invitae Corporation
  • NeoGenomics Laboratories
  • QIAGEN N.V.
  • Agilent Technologies, Inc.

Report Scope

In this report, the Global PARP Inhibitor Biomarkers Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

PARP Inhibitor Biomarkers Market, By Product

  • Kits
  • Assays

PARP Inhibitor Biomarkers Market, By Services

  • BRCA 1 & 2 Testing
  • HRD Testing
  • HRR Testing
  • Others

PARP Inhibitor Biomarkers Market, By Application

  • Breast Cancer
  • Ovarian Cancer
  • Others

PARP Inhibitor Biomarkers Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global PARP Inhibitor Biomarkers Market.

Available Customizations:

Global PARP Inhibitor Biomarkers Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global PARP Inhibitor Biomarkers Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Product (Kits, Assays)
    • 5.2.2. By Services (BRCA 1 & 2 Testing, HRD Testing, HRR Testing, Others)
    • 5.2.3. By Application (Breast Cancer, Ovarian Cancer, Others)
    • 5.2.4. By Region
    • 5.2.5. By Company (2025)
  • 5.3. Market Map

6. North America PARP Inhibitor Biomarkers Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Product
    • 6.2.2. By Services
    • 6.2.3. By Application
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States PARP Inhibitor Biomarkers Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Product
        • 6.3.1.2.2. By Services
        • 6.3.1.2.3. By Application
    • 6.3.2. Canada PARP Inhibitor Biomarkers Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Product
        • 6.3.2.2.2. By Services
        • 6.3.2.2.3. By Application
    • 6.3.3. Mexico PARP Inhibitor Biomarkers Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Product
        • 6.3.3.2.2. By Services
        • 6.3.3.2.3. By Application

7. Europe PARP Inhibitor Biomarkers Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Product
    • 7.2.2. By Services
    • 7.2.3. By Application
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany PARP Inhibitor Biomarkers Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Product
        • 7.3.1.2.2. By Services
        • 7.3.1.2.3. By Application
    • 7.3.2. France PARP Inhibitor Biomarkers Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Product
        • 7.3.2.2.2. By Services
        • 7.3.2.2.3. By Application
    • 7.3.3. United Kingdom PARP Inhibitor Biomarkers Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Product
        • 7.3.3.2.2. By Services
        • 7.3.3.2.3. By Application
    • 7.3.4. Italy PARP Inhibitor Biomarkers Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Product
        • 7.3.4.2.2. By Services
        • 7.3.4.2.3. By Application
    • 7.3.5. Spain PARP Inhibitor Biomarkers Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Product
        • 7.3.5.2.2. By Services
        • 7.3.5.2.3. By Application

8. Asia Pacific PARP Inhibitor Biomarkers Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Product
    • 8.2.2. By Services
    • 8.2.3. By Application
    • 8.2.4. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China PARP Inhibitor Biomarkers Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Product
        • 8.3.1.2.2. By Services
        • 8.3.1.2.3. By Application
    • 8.3.2. India PARP Inhibitor Biomarkers Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Product
        • 8.3.2.2.2. By Services
        • 8.3.2.2.3. By Application
    • 8.3.3. Japan PARP Inhibitor Biomarkers Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Product
        • 8.3.3.2.2. By Services
        • 8.3.3.2.3. By Application
    • 8.3.4. South Korea PARP Inhibitor Biomarkers Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Product
        • 8.3.4.2.2. By Services
        • 8.3.4.2.3. By Application
    • 8.3.5. Australia PARP Inhibitor Biomarkers Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Product
        • 8.3.5.2.2. By Services
        • 8.3.5.2.3. By Application

9. Middle East & Africa PARP Inhibitor Biomarkers Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Product
    • 9.2.2. By Services
    • 9.2.3. By Application
    • 9.2.4. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia PARP Inhibitor Biomarkers Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Product
        • 9.3.1.2.2. By Services
        • 9.3.1.2.3. By Application
    • 9.3.2. UAE PARP Inhibitor Biomarkers Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Product
        • 9.3.2.2.2. By Services
        • 9.3.2.2.3. By Application
    • 9.3.3. South Africa PARP Inhibitor Biomarkers Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Product
        • 9.3.3.2.2. By Services
        • 9.3.3.2.3. By Application

10. South America PARP Inhibitor Biomarkers Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Product
    • 10.2.2. By Services
    • 10.2.3. By Application
    • 10.2.4. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil PARP Inhibitor Biomarkers Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Product
        • 10.3.1.2.2. By Services
        • 10.3.1.2.3. By Application
    • 10.3.2. Colombia PARP Inhibitor Biomarkers Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Product
        • 10.3.2.2.2. By Services
        • 10.3.2.2.3. By Application
    • 10.3.3. Argentina PARP Inhibitor Biomarkers Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Product
        • 10.3.3.2.2. By Services
        • 10.3.3.2.3. By Application

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global PARP Inhibitor Biomarkers Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Myriad Genetics, Inc.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Ambry Genetics
  • 15.3. Thermo Fisher Scientific, Inc.
  • 15.4. Illumina, Inc.
  • 15.5. CENTOGENE N.V.
  • 15.6. Amoy Diagnostics Co., Ltd.
  • 15.7. Invitae Corporation
  • 15.8. NeoGenomics Laboratories
  • 15.9. QIAGEN N.V.
  • 15.10. Agilent Technologies, Inc.

16. Strategic Recommendations

17. About Us & Disclaimer